[Skip to Content]
[Skip to Content Landing]
Medical News & Perspectives
May 5, 2010

Aggressive Lipid, Hypertension Targeting Yields No Benefit for Some With Diabetes

JAMA. 2010;303(17):1681-1683. doi:10.1001/jama.2010.492

Atlanta—New research suggests that aggressively treating lipid levels and hypertension in certain patients with diabetes with the aim of preventing cardiovascular morbidity and mortality does no better in this regard than standard care—and may even be harmful. Whether such approaches need to be reconsidered for the general population remains to be seen.

The findings were presented at the American College of Cardiology's (ACC’s) Annual Scientific Session held here in March. Taking center stage were results from arms of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial that assessed the effects of combination lipid therapies and intensive blood pressure control. The unfavorable results from these arms joined the findings from the intensive glucose-lowering arm of ACCORD, which was stopped early in 2008 because intensive therapy increased mortality and did not significantly reduce major cardiovascular events (Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med. 2008;358[24]:2545-2559).

First Page Preview View Large
First page PDF preview
First page PDF preview